The Stanford Cancer Institute Partners with Nation’s Top Cancer Centers to Endorse Goal of Eliminating HPV-related Cancers in the United States
Photo courtesy of the NCI
Translating Stanford discoveries into individualized cancer care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Frequent skin cancers due to mutations in genes responsible for repairing DNA are linked to a threefold risk of unrelated cancers, according to a Stanford study. The finding could help identify people for more vigilant screening.
Scientists at Stanford used the wire to capture free-floating tumor cells in the blood, a technique that soon could be used in humans to yield an earlier cancer diagnosis.
A Stanford collaboration between clinical and basic science researchers has led to the identification of a compound that could improve the quality of life for head and neck cancer patients.